Published • loading... • Updated
Active Ingredients, Acquisitions and Spin-offs: Will Bayer, Novo Nordisk, BioNxt, or Evotec Become Top M&A Targets?
Summary by themarketonline.ca
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Active Ingredients, Acquisitions and Spin-offs: Will Bayer, Novo Nordisk, BioNxt, or Evotec Become Top M&A Targets?
Evotec: Restructuring Continues Will this work out? The Hamburg-based biotech company Evotec once again shocked the capital markets in July with a drastic downward revision of its forecast, as delayed milestone payments for the current year now point to a negative adjusted consolidated EBITDA of up to minus EUR 105 million. Analysts from renowned firms such as Deutsche Bank and Berenberg reacted skeptically and sharply slashed their price target…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
